As a further matter, genetically engineered bacteria represent a promising approach to modulate the gut microbiota, being designed to express therapeutic agents that enhance satiety and boost sensitivity to leptin, while also serving as a delivery system for therapeutic molecules targeting obesity-related conditions that are otherwise challenging to administer [158]. The gene discussed is LEP; the disease is obesity disorder.